Analyst Concerns On Vertex's Approved Drug By: Benzinga via Benzinga June 25, 2014 at 09:14 AM EDT HC Wainwright cut its rating on Vertex Pharmaceuticals (NASDAQ: VRTX) to Neutral after the stock rallied nearly 50 percent ... Read More >> Related Stocks: Vertex Pharmaceuticals